Charles George Drake MD

Director of genitourinary oncology and associate director for clinical research at the Herbert Irving Comprehensive Cancer Center

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1999 - 2002
Johns Hopkins UniversityResidency, Internal Medicine, 1997 - 1999
University of Colorado School of Medicine Anschutz Medical CampusClass of 1997

CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

PubMed

Molecular Characterization of KLK2 RNA Expression in Prostate Cancer.
Rana R McKay, Shayan S Nazari, Andrew Elliott, Norm Smith, Pedro Barata
Clinical Cancer Research. 2026-06-01
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.
Casey R Ager, Aleksandar Obradovic, Patrick McCann, Matthew Chaimowitz, Alexander L E Wang
Cell Reports. Medicine. 2026-03-17
Metabolic Reprogramming of T Cells by Dual UCP2 and IL-17 Blockade Enhances Immunity Against Pancreatic Cancer.
Chuan-Teng Liu, Chun-Chieh Yeh, Tsai-Chen Wu, Chia-Hsin Lin, Yi-Ting Kuo
Advanced Science. 2026-03-01

Journal Articles

A Role for Paracrine Interleukin‐6 Signaling in the Tumor Microenvironment in Prostate Tumor Growth
Charles Drake, MD, The Prostate
And Inflammation in Prostate Cancer Initiation
Charles Drake, MD, Development
Expression of LAG‐3 and Efficacy of Combination Treatment with Anti‐LAG‐3 and Anti‐PD‐1 Monoclonal Antibodies in Glioblastoma
Charles Drake, MD, International Journal of Cancer

Abstracts/Posters

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma
Charles G Drake, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant...
2019 ASCO Annual Meeting - 6/1/2019
PD-L1: Prognostic and Predictive State of the Science
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prosta...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

JnJ Seeks Indication Extension of Akeega from EMA for Adults with Metastatic Hormone-Sensitive Prostate Cancer, HRR Gene AlterationsJuly 5th, 2025
Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-Altered mCSPCJune 3rd, 2025
News & PublicationsMay 1st, 2024

Role Of Tc17 Cells In Tumor ImmunotherapyNational Cancer Institute2012
Blockade Of The Immune Checkpoint Mediated By B7-H1 In Men With Prostate CancerNational Cancer Institute2008–2011
Analysis Of LAG-3 In Regulatory T Cell Function And Immune SupressionNational Cancer Institute2008–2011
Regulation Of The Immune Response To Prostate CancerNational Cancer Institute2003–2007

BCBS Blue Card PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment